TY - JOUR
T1 - Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody
AU - Asano, Ryutaro
AU - Ikoma, Keiko
AU - Sone, Yukiko
AU - Kawaguchi, Hiroko
AU - Taki, Shintaro
AU - Hayashi, Hiroki
AU - Nakanishi, Takeshi
AU - Umetsu, Mitsuo
AU - Katayose, Yu
AU - Unno, Michiaki
AU - Kudo, Toshio
AU - Kumagai, Izumi
PY - 2010/7/2
Y1 - 2010/7/2
N2 - We previously reported the utility for cancer immunotherapy of a humanized bispecific diabody (hEx3) that targets epidermal growth factor receptor and CD3. Here, we used dynamic and static light scattering measurements to show that the multimer fraction observed in hEx3 in solution is a monodisperse tetramer. The multimerization into tetramers increased the inhibition of cancer cell growth by the hEx3 diabody. Furthermore, 1:2 stoichiometric binding for both antigens was observed in a thermodynamic analysis, indicating that the tetramer has bivalent binding activity for each target, and the structure may be in a circular configuration, as is the case for the single-chain Fv tetrabody. In addition to enhanced cytotoxicity, the functional affinity and stability of the hEx3 tetrabody were superior to those of the hEx3 diabody. The increase in molecular weight is also expected to improve the pharmacokinetics of the bispecific diabody, making the hEx3 tetrabody attractive as a therapeutic antibody fragment for cancer immunotherapy.
AB - We previously reported the utility for cancer immunotherapy of a humanized bispecific diabody (hEx3) that targets epidermal growth factor receptor and CD3. Here, we used dynamic and static light scattering measurements to show that the multimer fraction observed in hEx3 in solution is a monodisperse tetramer. The multimerization into tetramers increased the inhibition of cancer cell growth by the hEx3 diabody. Furthermore, 1:2 stoichiometric binding for both antigens was observed in a thermodynamic analysis, indicating that the tetramer has bivalent binding activity for each target, and the structure may be in a circular configuration, as is the case for the single-chain Fv tetrabody. In addition to enhanced cytotoxicity, the functional affinity and stability of the hEx3 tetrabody were superior to those of the hEx3 diabody. The increase in molecular weight is also expected to improve the pharmacokinetics of the bispecific diabody, making the hEx3 tetrabody attractive as a therapeutic antibody fragment for cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=77954221573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954221573&partnerID=8YFLogxK
U2 - 10.1074/jbc.M110.120444
DO - 10.1074/jbc.M110.120444
M3 - Article
C2 - 20444691
AN - SCOPUS:77954221573
SN - 0021-9258
VL - 285
SP - 20844
EP - 20849
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 27
ER -